Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Asthma, including pediatric asthma, or asthma-COPD overlap syndrome (ACOS)
• •Significant pulmonary disease other than COPD
• •Long-term oxygen therapy \>4.0 L/min or requirement of \>2.0 L/min to maintain oxygen saturation \>88% at rest
• •Unstable disorder that can impact participants safety or study outcomes
• •Active or incompletely treated tuberculosis
• •Current or past malignancies
• •Concomitant therapies:
• •* long-term macrolides or phosphodiesterase Type 3 (PDE-3) or PDE-4 inhibitors unless on stable therapy for \> 6 months
• •* any biologic therapy or systemic immunosuppressant within 4 months or 5 half-lives prior to Screening
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.